|
Variables
|
Unmatched cohort
|
Propensity score-matched cohort
|
|---|
|
Thoracotomy (n = 223)
|
VATS (n = 132)
|
P value
|
Thoracotomy (n = 102)
|
VATS (n = 102)
|
P value
|
|---|
|
Harvested LN number
|
22 (16.0–30.0)
|
16 (12.0–22.0)
|
< 0.001
|
22.5 (17.0–29.8)
|
16 (11.0–22.8)
|
< 0.001
|
|
Bronchial margin
| | | | | | |
|
R0
|
222 (99.6%)
|
132 (100%)
|
> 0.999
|
111 (100%)
|
111 (100%)
|
> 0.999
|
|
R1
|
1 (0.4%)
|
0 (0.0%)
| |
0 (0%)
|
0 (0%)
| |
|
Hospital length of stay
|
8 (6.0–11.0)
|
6 (5.0–8.0)
|
< 0.001
|
7 (6.0–10.0)
|
6 (5.0–8.0)
|
< 0.001
|
|
30-day morbidity
|
94 (42.2%)
|
42 (31.8%)
|
0.053
|
41 (40.2%)
|
32 (31.4%)
|
0.188
|
|
30-day mortality
|
2 (0.9%)
|
0 (0.0%)
|
0.147
|
1 (1%)
|
0 (0%)
|
> 0.999
|
|
Pathologic tumor size
|
60 (52.5–74)
|
55 (45–64.5)
|
< 0.001
|
55.5 (50–65)
|
56 (48–65)
|
0.348
|
|
Pathologic N stage
| | | | | | |
|
pN0
|
169 (75.8%)
|
106 (80.3%)
|
0.147
|
72 (70.6%)
|
86 (84.3%)
|
0.143
|
|
pN1
|
29 (13.0%)
|
9 (6.8%)
| |
18 (17.6%)
|
5 (4.9%)
| |
|
pN2
|
25 (11.2%)
|
16 (12.1%)
| |
12 (11.8%)
|
11 (10.8%)
| |
|
Visceral pleural invasion
|
38 (17.0%)
|
28 (21.2%)
|
0.404
|
25 (24.5%)
|
23 (22.5%)
|
0.864
|
|
Adjuvant treatment
| | | | | | |
|
No adjuvant treatment
|
93 (41.7%)
|
65 (49.2%)
|
0.204
|
43 (42.2%)
|
53 (52%)
|
0.262
|
|
Chemotherapy
|
110 (49.3%)
|
62 (47%)
| |
52 (51%)
|
46 (45.1%)
| |
|
Radiotherapy
|
7 (3.1%)
|
1 (0.7%)
| |
1 (1%)
|
1 (1%)
| |
|
Chemoradiotherapy
|
13 (5.8%)
|
4 (3%)
| |
6 (5.9%)
|
2 (2%)
| |
- Data are presented as number (%) or median (interquartile range)
